

Regimen Reference Order

MYEL – DVd (SUBCUTANEOUS daratumumab injection)

ARIA: MYEL - [DVd (SUBCUT)]

Planned Course: Until disease progression or unacceptable toxicity (1 cycle = 28 days)

Indication for Use: Relapsed/Refractory Multiple Myeloma

CVAD: Not Required

Proceed with treatment if:

Day 1 ONLY

ANC equal to or greater than $1 \times 10^9/L$ AND Platelets equal to or greater than $30 \times 10^9/L$

❖ Contact Hematologist if parameters not met

Note: Hepatitis B serology results must be reviewed in accordance with CCMB Policy Hepatitis B Monitoring for Oncology and Hematology Patients

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

| Drug | Dose | CCMB Administration Guideline |
|----------------|------|-------------------------------|
| Not Applicable | | |

Treatment Regimen – MYEL – DVd (SUBCUTANEOUS daratumumab injection)

| Drug | Dose | CCMB Administration Guideline |
|-------------------------------|------------------------------|---|
| Cycle 1 | | |
| dexamethasone | 40 mg | Orally once daily in the morning with food on Days 1, 8, 15 and 22 (Self-administered at home) |
| cetirizine | 10 mg | Orally 1 hour prior to daratumumab on Days 1, 8, 15 and 22 |
| acetaminophen | 975 mg | Orally 1 hour prior to daratumumab on Days 1, 8, 15 and 22 |
| montelukast | 10 mg | Orally 1 hour prior to daratumumab on Day 1 ONLY |
| bortezomib | 1.5 mg/m ² | Subcutaneous injection once weekly on Days 1, 8, 15 and 22 |
| daratumumab (Subcutaneous) | 1800 mg (1800 mg = 15 mL) | Subcutaneous: Administer over 3 to 5 minutes into abdomen on Days 1, 8, 15 and 22 Remove vial from refrigerator 30 minutes prior to preparing dose to bring to ambient temperature (15°C to 30°C) Use 23G needle <i>*Nursing Alert: Ensure subcutaneous daratumumab formulation is used (daratumumab-hyaluronidase)</i> |
| Cycle 2 | | |
| dexamethasone | 40 mg | Orally once daily in the morning with food on Days 1, 8, 15 and 22 (Self-administered at home) |

| | | |
|--|------------------------------|--|
| bortezomib | 1.5 mg/m ² | Subcutaneous injection once weekly on Days 1, 8, 15 and 22 |
| daratumumab (Subcutaneous) | 1800 mg (1800 mg = 15 mL) | Subcutaneous: Administer over 3 to 5 minutes into abdomen on Days 1, 8, 15 and 22 Remove vial from refrigerator 30 minutes prior to preparing dose to bring to ambient temperature (15°C to 30°C) Use 23G needle <i>*Nursing Alert: Ensure subcutaneous daratumumab formulation is used (daratumumab-hyaluronidase)</i> |
| Cycles 3 and 4 | | |
| dexamethasone | 40 mg | Orally once daily in the morning with food on Days 1, 8, 15 and 22 (Self-administered at home) |
| bortezomib | 1.5 mg/m ² | Subcutaneous injection once weekly on Days 1, 8, 15 and 22 |
| daratumumab (Subcutaneous) | 1800 mg (1800 mg = 15 mL) | Subcutaneous: Administer over 3 to 5 minutes into abdomen on Days 1 and 15 Remove vial from refrigerator 30 minutes prior to preparing dose to bring to ambient temperature (15°C to 30°C) Use 23G needle <i>*Nursing Alert: Ensure subcutaneous daratumumab formulation is used (daratumumab-hyaluronidase)</i> |
| Cycles 5 to 8 | | |
| dexamethasone | 40 mg | Orally once daily in the morning with food on Days 1, 8, 15 and 22 (Self-administered at home) |
| bortezomib | 1.5 mg/m ² | Subcutaneous injection once weekly on Days 1, 8, 15 and 22 |
| daratumumab (Subcutaneous) | 1800 mg (1800 mg = 15 mL) | Subcutaneous: Administer over 3 to 5 minutes into abdomen on Day 1 Remove vial from refrigerator 30 minutes prior to preparing dose to bring to ambient temperature (15°C to 30°C) Use 23G needle <i>*Nursing Alert: Ensure subcutaneous daratumumab formulation is used (daratumumab-hyaluronidase)</i> |
| Cycle 9* and Onwards | | |
| dexamethasone | 20 mg | Orally once in the morning with food on Day 1 (Self-administered at home) |
| daratumumab (Subcutaneous) | 1800 mg (1800 mg = 15 mL) | Subcutaneous: Administer over 3 to 5 minutes into abdomen on Day 1 Remove vial from refrigerator 30 minutes prior to preparing dose to bring to ambient temperature (15°C to 30°C) Use 23G needle <i>*Nursing Alert: Ensure subcutaneous daratumumab formulation is used (daratumumab-hyaluronidase)</i> |
| <p>*At physician's discretion, bortezomib may be prescribed Cycle 9 and onwards as maintenance on Days 1 and 15 All doses will be automatically rounded that fall within CCMB Approved Dose Bands. See Dose Banding Document for more information</p> | | |

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

Hepatitis B serology

- Hepatitis B surface antigen and Hepatitis B core antibody (drawn within preceding 5 years)

Baseline

- RBC serology (genotyping) mandatory prior to starting daratumumab

Cycles 1 to 8

Day 1

- CBC, serum creatinine, urea, electrolytes, liver enzymes, total bilirubin, albumin and glucose as per Physician Orders
- Serum Protein Electrophoresis (SPEP)/Free Light Chain Ratio (FLCH) (response assessment)

Days 8, 15 and 22

- No blood work required

Cycle 9 and Onwards

Day 1

- CBC, serum creatinine, urea, electrolytes, liver enzymes, total bilirubin, albumin and glucose as per Physician Orders
- SPEP/FLCH (response assessment)

daratumumab monitoring

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as clinically indicated
- No observation period is required after subcutaneous daratumumab administration. Patient can be discharged from treatment room if stable whether they had a reaction or not

Recommended Support Medications

| Drug | Dose | CCMB Administration Guideline |
|--|---------------------------|--|
| valACYclovir | 500 mg | Orally once daily |
| fluticasone and salmeterol combination | 100 mcg – 50 mcg per dose | Prescribed at physician's discretion If patient has a history of asthma or COPD, 1 inhalation twice daily only as needed post daratumumab injection |

DISCHARGE INSTRUCTIONS

All Cycles

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Remind patient to take recommended support medications at home

Cycles 1 to 8

- dexamethasone is a cancer therapy in this treatment regimen. Remind patient to take dexamethasone at home
- bortezomib has potential for drug-drug interactions. Patients should notify clinic prior to starting any new medication
- Advise patient to avoid green tea to prevent interactions with bortezomib
- Avoid grapefruit and grapefruit juice, Seville oranges (i.e. orange marmalade) and starfruit
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- Due to the risk of reactivation of Hepatitis B virus (HBV) while on this treatment regimen, prescriber must adhere to CCMB Policy ***Hepatitis B Monitoring for Oncology and Hematology Patients*** for ordering and interpreting HBV serology and prescribing antiviral prophylaxis
- daratumumab interferes with cross-matching and red blood cell antibody screening. **Indicate on all Canadian Blood Services requisitions that the patient is on daratumumab**
- daratumumab may interfere with the interpretation of the Serum Protein Electrophoresis (SPEP) results. **Indicate on all immunology (SPEP) requisitions that the patient is on daratumumab**
- Administering nurse must document any infusion-related reactions with any dose of daratumumab
- Consideration may be given to reducing dexamethasone dose at the physician's discretion to 20 mg for patients older than 75 years or who have a body mass index of less than 18.5 kg/m²
- valACYclovir (shingles prophylaxis) continues while on treatment and for 1 month after discontinuation of treatment due to risk of prolonged immunosuppression
- All patients should be considered for bisphosphonate therapy
- **Note: At Cycles 2 and 9**, an entry called **"Physician Reminder – dexamethasone dose evaluation"** will appear in the electronic drug order. **No action is required. This prompt is to remind the prescriber to evaluate the dexamethasone dose that begins at Cycles 2 and 9**